Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier

Current Medicinal Chemistry

Volumn 20, Issue 17, 2013, Pages 2212-2225

  Tosi, G ^a   Bortot, B ^b   Ruozi, B ^a   Dolcetta, D ^c   Vandelli, M A ^a   Forni, F ^a   Severini, G M ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c 'Mauro Baschirotto' Institute for Rare Diseases   (Italy)

Author keywords

Blood brain barrier; Brain targeting; Drug delivery; Gene therapy; Lysosomal storage disorders; Nanoparticles; PLGA

Indexed keywords

CEREBROSIDE SULFATASE; GLYCOPEPTIDE; LEUPRORELIN; LIPOSOME; NANOPARTICLE; POLYGLACTIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; DNA INTEGRATION; DNA VECTOR; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME REPLACEMENT; GENE TARGETING; GENE THERAPY; GLIA CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VIVO STUDY; NANOTECHNOLOGY; NERVE CELL; NONHUMAN; PARENCHYMA; STORAGE DISEASE; SURFACE PROPERTY; TRANSPOSON;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG CARRIERS; ENZYME REPLACEMENT THERAPY; GENETIC THERAPY; HUMANS; LACTIC ACID; LYSOSOMAL STORAGE DISEASES; NANOPARTICLES; PEPTIDES; PHARMACEUTICAL PREPARATIONS; POLYGLYCOLIC ACID;

EID: 84877953644     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320170006     Document Type: Article

References (177)

1. Bamrungsap, S.; Zhao, Z.; Chen, T.; Wang, L.; Li, C.; Fu, T.; Tan, W. Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system. Nanomedicine, 2012, 7(8), 1253-1271.
2. Parveen, S.; Misra, R.; Sahoo, S.K. Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine, 2012, 8(2), 147-166.
3. Sanvicens, N.; Marco, M.P.; Multifunctional nanoparticles-properties and prospects for their use in human medicine. Trends Biotechnol., 2008, 26(8), 425-433.
4. Wagner, V.; Dullaart, A.; Bock, A.K.; Zweck, A.; The emerging nanomedicine landscape. Nat. Biotechnol., 2006, 24(10), 1211-1217. (Pubitemid 44564760)
5. Gabizon, A.; Goren, D.; Cohen, R.; Barenholz, Y.; Development of liposomal anthracyclines: From basics to clinical applications. J. Control Release, 1998, 53(1-3), 275-279. (Pubitemid 28218710)
6. Alberts, D.; Ranger-Moore, J.; Einspahr, J.; Saboda, K.; Bozzo, P.; Liu, Y.; Xu, X.C.; Lotan, R.; Warneke, J.; Salasche, S.; Stratton, S.; Levine, N.; Goldman, R.; Islas, M.; Duckett, L.; Thompson, D.; Bartels, P.; Foote, J. Safety and efficacy of dose-intensive oral vitamin A in subjects with sun-damaged skin. Clin. Cancer. Res., 2004, 10(6), 1875-1880. (Pubitemid 38375542)
7. Allen, T.M.; Martin, F.J. Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol., 2004, 3(6 Suppl 13), 5-15. (Pubitemid 40023239)
8. Meunier, F.; Prentice, H. G.; Ringden, O. Liposomal amphotericin B (AmBisome): Safety data from a phase II/III clinical trial. J. Antimicrob. Chemother., 1991, 28 Suppl B 83-91.
9. Eifler, A.C.; Thaxton, C.S. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol. Biol., 2011, 726, 325-338.
10. Hawkins, M. J.; Soon-Shiong, P.; Desai, N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug. Deliv. Rev., 2008, 60(8), 876-885.
11. Nijhara, R.; Balakrishnan, K. Bringing nanomedicines to market: Regulatory challenges, opportunities, and uncertainties. Nanomedicine, 2006, 2(2), 127-136. (Pubitemid 43956611)
12. Ai, J.; Biazar, E.; Jafarpour, M.; Montazeri, M.; Majdi, A.; Aminifard, S.; Zafari, M.; Akbari, H.R.; Rad, H.G. Nanotoxicology and nanoparticle safety in biomedical designs. Int. J. Nanomedicine, 2011, 6, 1117-1127.
13. Moghimi, S. M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid. Res., 2003, 42(6), 463-478. (Pubitemid 37237636)
14. Shi, J.; Xiao, Z.; Kamaly, N.; Farokhzad, O.C. Self-assembled targeted nanoparticles: Evolution of technologies and bench to bedside translation. Acc. Chem. Res., 2011, 44(10), 1123-1134.
15. Hrkach, J.; Von Hoff, D.; Mukkaram Ali, M.; Andrianova, E.; Auer, J.; Campbell, T.; De Witt, D.; Figa, M.; Figueiredo, M.; Horhota, A.; Low, S.; McDonnell, K.; Peeke, E.; Retnarajan, B.; Sabnis, A.; Schnipper, E.; Song, J.J.; Song, Y.H.; Summa, J.; Tompsett, D.; Troiano, G.; Van Geen Hoven, T.; Wright, J.; Lo-Russo, P.; Kantoff, P.W.; Bander, N.H.; Sweeney, C.; Farokhzad, O.C.; Langer, R.; Zale, S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med., 2012, 4(128), 128ra139.
16. Yoo, J.Y.; Kim, J.M.; Seo, K.S.; Jeong, Y.K.; Lee, H.B.; Khang, G. Characterization of degradation behavior for PLGA in various pH condition by simple liquid chromatography method. Biomed. Mater. Eng., 2005, 15(4), 279-288. (Pubitemid 40991530)
17. Kumari, A.; Yadav, S.K.; Yadav, S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B. Biointerfaces, 2010, 75(1), 1-18.
18. Vert, M.; Mauduit, J.; Li, S. Biodegradation of PLA/GA polymers: Increasing complexity. Biomaterials, 1994, 15(15), 1209-1213.
19. Miller, R. A.; Brady, J. M.; Cutright, D. E; Degradation rates of oral resorbable implants (polylactates and polyglycolates): Rate modification with changes in PLA/PGA copolymer ratios. J. Biomed. Mater. Res., 1977, 11(5), 711-719. (Pubitemid 8159588)
20. Belbella, A.; Vauthier, C.; Fessi, H.; Devissaguet, J. P.; Puisieux, F. In vitro degradation of nanospheres from poly(D,L-lactides) of different molecular weights and polydispersity. Int. J. Pharm., 1996, 129(1-2), 95-102. (Pubitemid 26097979)
21. Lemoine, D.; Francois, C.; Kedzierewicz, F.; Preat, V.; Hoffman, M.; Maincent, P. Stability study of nanoparticles of poly(epsiloncaprolactone), poly(D,L-lactide) and poly(D,L-lactide-coglycolide). Biomaterials, 1996, 17(22), 2191-2197. (Pubitemid 26364773)
22. Mittal, G.; Sahana, D.K.; Bhardwaj, V.; Ravi Kumar, M.N. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Control Release, 2007, 119(1), 77-85. (Pubitemid 46561546)
23. Dunne, M.; Corrigan, I.; Ramtoola, Z. Influence of particle size and dissolution conditions on the degradation properties of polylactideco-glycolide particles. Biomaterials, 2000, 21(16), 1659-1668. (Pubitemid 30347308)
24. Panyam, J.; Dali, M.M.; Sahoo, S.K.; Ma, W.; Chakravarthi, S.S.; Amidon, G.L.; Levy, R.J.; Labhasetwar, V. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-coglycolide) nano-and microparticles. J. Control Release, 2003, 92(1-2), 173-187. (Pubitemid 37130131)
25. Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm., 2008, 5(4), 505-515.
26. Minchin, R. Nanomedicine: Sizing up targets with nanoparticles. Nat. Nanotechnol., 2008, 3(1), 12-13.
27. Yadav, K.S.; Chuttani, K.; Mishra, A.K.; Sawant, K.K. Effect of Size on the Biodistribution and Blood Clearance of Etoposide-Loaded PLGA Nanoparticles. PDA. J. Pharm. Sci. Technol., 2011, 65(2), 131-139.
28. Nagayama, S.; Ogawara, K.; Fukuoka, Y.; Higaki, K.; Kimura, T. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int. J. Pharm., 2007, 342(1-2), 215-221. (Pubitemid 47259322)
29. Hirn, S.; Semmler-Behnke, M.; Schleh, C.; Wenk, A.; Lipka, J.; Schaffler, M.; Takenaka, S.; Moller, W.; Schmid, G.; Simon, U.; Kreyling, W.G. Particle size-dependent and surface chargedependent biodistribution of gold nanoparticles after intravenous administration. Eur. J. Pharm. Biopharm., 2011, 77(3), 407-416.
30. Dufort, S.; Sancey, L.; Coll, J.L.; Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv. Drug. Deliv. Rev., 2012, 64(2), 179-189.
31. Owens, D.E. 3rd; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 2006, 307(1), 93-102. (Pubitemid 41773257)
32. Kim, D.; El-Shall, H.; Dennis, D.; Morey, T. Interaction of PLGA nanoparticles with human blood constituents. Colloids Surf. B. Biointerfaces, 2005, 40(2), 83-91. (Pubitemid 40092448)
33. Yadav, S.C.; Kumari, A.; Yadav, R. Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation. Peptides, 2011, 32(1), 173-187.
34. Weiss, B.; Schneider, M.; Muys, L.; Taetz, S.; Neumann, D.; Schaefer, U.F.; Lehr, C.M. Coupling of biotin-(poly(ethylene glycol)) amine to poly(D,L-lactide-co-glycolide) nanoparticles for versatile surface modification. Bioconjug. Chem., 2007, 18(4), 1087-1094. (Pubitemid 47122628)
35. Kirpotin, D.; Park, J.W.; Hong, K.; Zalipsky, S.; Li, W.L.; Carter, P.; Benz, C.C.; Papahadjopoulos, D. Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro. Biochemistry,1997, 36(1), 66-75. (Pubitemid 27024679)
36. Meyer, O.; Kirpotin, D.; Hong, K.; Sternberg, B.; Park, J.W.; Woodle, M.C.; Papahadjopoulos, D. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J. Biol. Chem., 1998, 273 (25), 15621-15627. (Pubitemid 28298176)
37. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y.J.; Preat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control Release, 2006, 116(1), 1-27. (Pubitemid 44792295)
38. Gvili, K.; Benny, O.; Danino, D.; Machluf, M. Poly(D,L-lactideco- glycolide acid) nanoparticles for DNA delivery: Waiving preparation complexity and increasing efficiency. Biopolymers, 2007, 85(5-6), 379-391. (Pubitemid 46649820)
39. Zolnik, B.S.; Gonzalez-Fernandez, A.; Sadrieh, N.; Dobrovolskaia, M.A. Nanoparticles and the immune system. Endocrinology, 2010, 151(2), 458-465.
40. Sarti, F.; Perera, G.; Hintzen, F.; Kotti, K.; Karageorgiou, V.; Kammona, O.; Kiparissides, C.; Bernkop-Schnurch, A. In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials, 2011, 32(16), 4052-4057.
41. Mishra, N.; Tiwari, S.; Vaidya, B.; Agrawal, G.P.; Vyas, S.P.; Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis. B. J. Drug. Target, 2011, 19(1), 67-78.
42. Akagi, T.; Baba, M.; Akashi, M. Biodegradable Nanoparticles as Vaccine. Adjuvants and Delivery Systems: Regulation of Immune Responses by Nanoparticle-Based Vaccine. Adv. Polym. Sci., 2011, 247,31-64.
43. Tosi, G.; Costantino, L.; Ruozi, B.; Forni, F.; Vandelli, M.A. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin. Drug. Deliv., 2008, 5(2), 155-174. (Pubitemid 351308309)
44. Costantino, L.; Tosi, G.; Ruozi, B.; Bondioli, L.; Vandelli, M.A.; Forni, F. Chapter 3 -Colloidal systems for CNS drug delivery. Prog. Brain. Res., 2009, 180, 35-69.
45. Tosi, G.; Fano, R. A.; Bondioli, L.; Badiali, L.; Benassi, R.; Rivasi, F.; Ruozi, B.; Forni, F.; Vandelli, M.A. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine, 2011, 6 (3), 423-436.
46. Ruozi, B.; Belletti, D.; Bondioli, L.; De Vita, A.; Forni, F.; Vandelli, M.A.; Tosi, G. Neurotrophic factors and neurodegenerative diseases: A delivery issue. Int. Rev. Neurobiol., 2012, 102, 207-247.
47. Tosi, G.; Ruozi, B.; Belletti, D.; Badiali, L.; Vandelli, M.A.; The Bridge between nanotechnology and neuroscience: Neuro-Nanomedicine. J. Neurosci., 2012, 2(1), 20-26.
48. Tosi, G.; Muresanu, D.F.; Sharma, A. Advances and perspectives for Central Nervous System drug delivery: The interface between nanotechnology and neuroscience. J. Neurosci., 2012, 2(1), 1-4.
49. Tosi, G.; Ruozi, B.; Belletti, D. Nanomedicine: The future for advancing medicine and neuroscience. Nanomedicine, 2012, 7(8), 1113-1116.
50. Bala, I.; Hariharan, S.; Kumar, M.N. PLGA nanoparticles in drug delivery: The state of the art. Crit Rev Ther. Drug. Carrier Syst., 2004, 21(5), 387-422. (Pubitemid 41647578)
51. Kocbek, P.; Obermajer, N.; Cegnar, M.; Kos, J.; Kristl, J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Control. Release, 2007, 120(1-2), 18-26. (Pubitemid 46874614)
52. Lu, J.M.; Wang, X.; Marin-Muller, C.; Wang, H.; Lin, P.H.; Yao, Q.; Chen, C. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert. Rev. Mol. Diagn., 2009, 9(4), 325-341.
53. Thierry, B. Drug nanocarriers and functional nanoparticles: Applications in cancer therapy. Curr. Drug. Deliv., 2009, 6(4), 391-403.
54. Acharya, S.; Sahoo, S.K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug. Deliv. Rev., 2011, 63(3), 170-183.
55. Dinarvand, R.; Sepehri, N.; Manoochehri, S.; Rouhani, H.; Atyabi, F. Polylactide-co-glycolide nanoparticles for Control led delivery of anticancer agents. Int. J. Nanomedicine, 2011, 6 877-895.
56. Jain, A.K.; Das, M.; Swarnakar, N.K.; Jain, S. Engineered PLGA nanoparticles: An emerging delivery tool in cancer therapeutics. Crit. Rev. Ther. Drug. Carrier. Syst., 2011, 28(1), 1-45.
57. Taurin, S.; Nehoff, H.; Greish, K. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J. Control. Release, 2012, 164(3), 265-275.
58. Choi, S.H.; Park, T.G. G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method. Int. J. Pharm., 2006, 311(1-2), 223-228.
59. Danhier, F.; Lecouturier, N.; Vroman, B.; Jerome, C.; Marchand-Brynaert, J.; Feron, O.; Preat, V. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J. Control Release, 2009, 133(1), 11-17.
60. Luo, G.; Jin, C.; Long, J.; Fu, D.; Yang, F.; Xu, J.; Yu, X.; Chen, W.; Ni, Q. RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles. Cancer. Biol. Ther., 2009, 8(7), 594-598.
61. Braden, A.R.; Kafka, M.T.; Cunningham, L.; Jones, H.; Vishwanatha, J.K. Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth. J. Nanosci. Nanotechnol., 2009, 9(5), 2856-2865.
62. McDermott, M.T.; Kidd, G.S. The role of calcitonin in the development and treatment of osteoporosis. Endocr. Rev., 1987, 8(4), 377-390.
63. Lamprecht, A.; Ubrich, N.; Yamamoto, H.; Schafer, U.; Takeuchi, H.; Maincent, P.; Kawashima, Y.; Lehr, C.M. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther., 2001, 299(2), 775-781.
64. Horisawa, E.; Hirota, T.; Kawazoe, S.; Yamada, J.; Yamamoto, H.; Takeuchi, H.; Kawashima, Y. Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm. Res., 2002, 19(4), 403-410. (Pubitemid 34408936)
65. Lamprecht, A.; Yamamoto, H.; Takeuchi, H.; Kawashima, Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J. Pharmacol. Exp. Ther., 2005, 315(1), 196-202. (Pubitemid 41380512)
66. Higaki, M.; Ishihara, T.; Izumo, N.; Takatsu, M.; Mizushima, Y. Treatment of experimental arthritis with poly(D, L-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate. Ann. Rheum. Dis., 2005, 64(8), 1132-1136. (Pubitemid 41113345)
67. Agnihotri, S.M.; Vavia, P.R. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine, 2009, 5(1), 90-95.
68. Araujo, J.; Vega, E.; Lopes, C.; Egea, M.A.; Garcia, M.L.; Souto, E.B. Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf. B. Biointerfaces, 2009, 72(1), 48-56.
69. Vij, N.; Min, T.; Marasigan, R.; Belcher, C.N.; Mazur, S.; Ding, H.; Yong, K.T.; Roy, I. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J. Nanobiotechnology, 2010, 8, 22.
70. Wang, Y.C.; Wu, Y.T.; Huang, H.Y.; Lin, H.I.; Lo, L.W.; Tzeng, S.F.; Yang, C.S. Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. Biomaterials, 2008, 29(34), 4546-4553.
71. Chappell, J.C.; Song, J.; Burke, C.W.; Klibanov, A.L.; Price, R.J. Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis. Small, 2008, 4(10), 1769-1777.
72. Golub, J.S.; Kim, Y.T.; Duvall, C.L.; Bellamkonda, R.V.; Gupta, D.; Lin, A.S.; Weiss, D.; Robert Taylor, W.; Guldberg, R.E. Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am. J. Physiol. Heart Circ. Physiol., 2010, 298(6), H1959-1965.
73. Klugherz, B.D.; Jones, P.L.; Cui, X.; Chen, W.; Meneveau, N.F.; DeFelice, S.; Connolly, J.; Wilensky, R L.; Levy, R.J. Gene delivery from a DNA Controlled-release stent in porcine coronary arteries. Nat. Biotechnol., 2000, 18(11), 1181-1184.
74. Cui, F.; Shi, K.; Zhang, L.; Tao, A.; Kawashima, Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J. Control. Release, 2006, 114(2), 242-250. (Pubitemid 44291843)
75. Liu, J.; Zhang, S.M.; Chen, P.P.; Cheng, L.; Zhou, W.; Tang, W.X.; Chen, Z.W.; Ke, C.M. Controlled release of insulin from PLGA nanoparticles embedded within PVA hydrogels. J. Mater. Sci. Mater. Med., 2007, 18(11), 2205-2210. (Pubitemid 350167371)
76. Lecaroz, M.C.; Blanco-Prieto, M.J.; Campanero, M.A.; Salman, H.; Gamazo, C. Poly(D,L-lactide-coglycolide) particles containing gentamicin: Pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. Antimicrob. Agents Chemother., 2007, 51(4), 1185-1190. (Pubitemid 46586792)
77. Gupta, H.; Aqil, M.; Khar, R.K.; Ali, A.; Bhatnagar, A.; Mittal, G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine, 2010, 6(2), 324-333.
78. Bondioli, L.; Ludovisi, A.; Tosi, G.; Ruozi, B.; Forni, F.; Pozio, E.; Vandelli, M.A.; Gomez-Morales, M.A. The loading of labelled antibody-engineered nanoparticles with Indinavir increases its in vitro efficacy against Cryptosporidium parvum. Parasitology, 2011, 138(11), 1384-1391.
79. Scott, C.J.; Marouf, W.M.; Quinn, D.J.; Buick, R.J.; Orr, S.J.; Donnelly, R.F.; McCarron, P.A. Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-co-glycolide) nanoparticles. Pharm. Res., 2008, 2 (1), 135-146.
80. Fievez, V.; Plapied, L.; des Rieux, A.; Pourcelle, V.; Freichels, H.; Wascotte, V.; Vanderhaeghen, M. L.; Jerome, C.; Vanderplasschen, A.; Marchand-Brynaert, J.; Schneider, Y.J.; Preat, V. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur. J. Pharm. Biopharm., 2009, 73(1), 16-24.
81. Molavi, O.; Ma, Z.; Hamdy, S.; Lavasanifar, A.; Samuel, J. Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124. Immunopharmacol. Immunotoxicol., 2009, 31(2), 214-221.
82. Liu, G.; Zhang, L.; Zhao, Y. Modulation of immune responses through direct activation of Toll-like receptors to T cells. Clin. Exp. Immunol., 2010, 160(2), 168-175.
83. Rajapaksa, T.E.; Stover-Hamer, M.; Fernandez, X.; Eckelhoefer, H.A.; Lo, D.D. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J. Control Release, 2010, 142(2), 196-205.
84. Hamdy, S.; Haddadi, A.; Shayeganpour, A.; Samuel, J.; Lavasanifar, A. Activation of antigen-specific T cell-responses by mannandecorated PLGA nanoparticles. Pharm. Res., 2011, 28(9), 2288-2301.
85. Yoo, H.S.; Park, T.G. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control Release, 2004, 96(2), 273-283. (Pubitemid 38481509)
86. Mo, Y.; Lim, L.Y. Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J. Control Release, 2005, 107(1), 30-42. (Pubitemid 41253700)
87. Zhang, Z.; Huey Lee, S.; Feng, S.S. Folate-decorated poly(lactideco- glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials, 2007, 28(10), 1889-1899. (Pubitemid 46137995)
88. Chen, H.; Gao, J.; Lu, Y.; Kou, G.; Zhang, H.; Fan, L.; Sun, Z.; Guo, Y.; Zhong, Y. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J. Control Release, 2008, 128(3), 209-216.
89. Dhar, S.; Gu, F.X.; Langer, R.; Farokhzad, O.C.; Lippard, S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U S A, 2008, 105(45), 17356-17361.
90. Chittasupho, C.; Xie, S.X.; Baoum, A.; Yakovleva, T.; Siahaan, T.J.; Berkland, C.J. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur. J. Pharm. Sci., 2009, 37(2), 141-150.
91. Wang, Z.; Chui, W.K.; Ho, P.C. Design of a multifunctional PLGA nanoparticulate drug delivery system: Evaluation of its physicochemical properties and anticancer activity to malignant cancer cells. Pharm. Res., 2009, 26(5), 1162-1171.
92. Danhier, F.; Vroman, B.; Lecouturier, N.; Crokart, N.; Pourcelle, V.; Freichels, H.; Jerome, C.; Marchand-Brynaert, J.; Feron, O.; Preat, V. Targeting of tumor endothelium by RGD-grafted PLGAnanoparticles loaded with paclitaxel. J. Control Release, 2009, 140(2), 166-173.
93. Patil, Y.; Sadhukha, T.; Ma, L.; Panyam, J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control Release, 2009, 136(1), 21-29.
94. Acharya, S.; Dilnawaz, F.; Sahoo, S.K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials, 2009, 30(29), 5737-5750.
95. Patil, Y.B.; Swaminathan, S.K.; Sadhukha, T.; Ma, L.; Panyam, J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials, 2010, 31(2), 358-365.
96. Luo, G.; Yu, X.; Jin, C.; Yang, F.; Fu, D.; Long, J.; Xu, J.; Zhan, C.; Lu, W. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int. J. Pharm., 2010, 385(1-2), 150-156.
97. Desgrosellier, J.S.; Cheresh, D.A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer, 2010, 10(1), 9-22.
98. Zhao, L.; Feng, S.S.; Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: In vitro and in vivo studies. J. Pharm. Sci., 2010, 99(8), 3552-3560.
99. Zheng, Y.; Yu, B.; Weecharangsan, W.; Piao, L.; Darby, M.; Mao, Y.; Koynova, R.; Yang, X.; Li, H.; Xu, S.; Lee, L.J.; Sugimoto, Y.; Brueggemeier, R.W.; Lee, R.J. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int. J. Pharm., 2010, 390(2), 234-241.
100. Jain, A.K.; Swarnakar, N.K.; Godugu, C.; Singh, R.P.; Jain, S.The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials, 2011, 32(2), 503-515.
101. Guo, J.; Gao, X.; Su, L.; Xia, H.; Gu, G.; Pang, Z.; Jiang, X.; Yao, L.; Chen, J.; Chen, H. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials, 2011, 32(31), 8010-8020.
102. Liang, C.; Yang, Y.; Ling, Y.; Huang, Y.; Li, T.; Li, X. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. Bioorg. Med. Chem., 2011, 19(13), 4057-4066.
103. Brambilla, D.; Le Droumaguet, B.; Nicolas, J.; Hashemi, S.H.; Wu, L. P.; Moghimi, S.M.; Couvreur, P.; Andrieux, K. Nanotechnologies for Alzheimer's disease: Diagnosis, therapy, and safety issues. Nanomedicine, 2011, 7(5), 521-540.
104. Chen, Y.; Liu, L. Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug. Deliv. Rev., 2012, 64(7), 640-665.
105. Nunes, A.; Al-Jamal, K.T.; Kostarelos, K. Therapeutics, imaging and toxicity of nanomaterials in the central nervous system. J. Control Release, 2012, 161(2), 290-306.
106. Gabathuler, R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis., 2010, 37(1), 48-57.
107. Witt, K.A.; Gillespie, T.J.; Huber, J.D.; Egleton, R.D.; Davis, T.P. Peptide drug modifications to enhance bioavailability and bloodbrain barrier permeability. Peptides, 2001, 22(12), 2329-2343.
108. Costantino, L.; Gandolfi, F.; Tosi, G.; Rivasi, F.; Vandelli, M.A.; Forni, F. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control Release, 2005, 108(1), 84-96. (Pubitemid 41476677)
109. Egleton, R.D.; Davis, T.P. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx., 2005, 2(1), 44-53. (Pubitemid 40128025)
110. Beddell, C.R.; Clark, R.B.; Hardy, G.W.; Lowe, L.A.; Ubatuba, F.B.; Vane, J.R.; Wilkinson, S. Structural requirements for opioid activity of analogues of the enkephalins. Proc. R. Soc. Lond. B Biol. Sci., 1977, 198(1132), 249-265. (Pubitemid 8165160)
111. Balodis, Y.Y.; Nikiforovich, G.V.; Grinsteine, I.V.; Vegner, R.E.; Chipens, G.I. Enkephalin: Structure-function relationships. FEBS Lett., 1978, 86(2), 239-242.
112. Costantino, L.; Gandolfi, F.; Bossy-Nobs, L.; Tosi, G.; Gurny, R.; Rivasi, F.; Vandelli, M.A.; Forni, F. Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures. Biomaterials, 2006, 27(26), 4635-4645. (Pubitemid 43783224)
113. Fessi, H.; Devissaguet, J. P.; Puisieux, F.; Thies, C. Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. US Patent No.5, 1992, 118 528.
114. Barichello, J.M.; Morishita, M.; Takayama, K.; Nagai, T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug. Dev. Ind. Pharm., 1999, 25(4), 471-476. (Pubitemid 29159426)
115. Zambaux, M.F.; Bonneaux, F.; Gref, R.; Maincent, P.; Dellacherie, E.; Alonso, M.J.; Labrude, P.; Vigneron, C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J. Control Release, 1998, 50(1-3), 31-40. (Pubitemid 28044098)
116. Vrignaud, S.; Benoit, J. P.; Saulnier, P. Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles. Biomaterials, 2011, 32(33), 8593-8604.
117. Kreuter, J.; Ramge, P.; Petrov, V.; Hamm, S.; Gelperina, S.E.; Engelhardt, B.; Alyautdin, R.; von Briesen, H.; Begley, D.J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res., 2003, 20(3), 409-416. (Pubitemid 36288370)
118. Polt, R.; Dhanasekaran, M.; Keyari, C.M. Glycosylated neuropeptides: A new vista for neuropsychopharmacology? Med. Res. Rev., 2005, 25(5), 557-585. (Pubitemid 41233371)
119. Tosi, G.; Costantino, L.; Rivasi, F.; Ruozi, B.; Leo, E.; Vergoni, A.V.; Tacchi, R.; Bertolini, A.; Vandelli, M.A.; Forni, F. Targeting the central nervous system: In vivo experiments with peptidederivatized nanoparticles loaded with Loperamide and Rhodamine-123. J. Control Release, 2007, 122(1), 1-9. (Pubitemid 47284547)
120. Vergoni, A.V.; Tosi, G.; Tacchi, R.; Vandelli, M.A.; Bertolini, A.; Costantino, L. Nanoparticles as drug delivery agents specific for CNS: In vivo biodistribution. Nanomedicine, 2009, 5(4), 369-377.
121. Tosi, G.; Bondioli, L.; Ruozi, B.; Badiali, L.; Severini, G. M.; Biffi, S.; De Vita, A.; Bortot, B.; Dolcetta, D.; Forni, F.; Vandelli, M.A. NIR-labeled nanoparticles engineered for brain targeting: In vivo optical imaging application and fluorescent microscopy evidences. J. Neural. Transm., 2011, 118(1), 145-153.
122. Tosi, G.; Ruozi, B.; Belletti, D.; Vilella, A.; Zoli, M.; Vandelli, M.A.; Forni, F. Brain-targeted polymeric nanoparticles: In vivo evidences after different routes of administration in rodents. Nanomedicine, 2012, accepted.
123. Tosi, G.; Rivasi, F.; Gandolfi, F.; Costantino, L.; Vandelli, M.A.; Forni, F. Conjugated poly(D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials, 2005, 26(19), 4189-4195. (Pubitemid 40138665)
124. Grabrucker, A.M.; Garner, C.C.; Boeckers, T.M.; Bondioli, L.; Ruozi, B.; Forni, F.; Vandelli, M.A.; Tosi, G. Development of novel Zn2+ loaded nanoparticles designed for cell-type targeted drug release in CNS neurons: In vitro evidences. PLoS One, 2011, 6(3), e17851.
125. Vellodi, A. Lysosomal storage disorders. Br. J. Haematol., 2005, 128(4), 413-431. (Pubitemid 40283160)
126. Brady, R.O.; Pentchev, P.G.; Gal, A.E.; Hibbert, S.R.; Dekaban, A.S. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N. Engl. J. Med., 1974, 291(19), 989-993.
127. Niederau, C.; vom Dahl, S.; Haussinger, D. First long-term results of imiglucerase therapy of type 1 Gaucher disease. Eur. J. Med. Res., 1998, 3(1-2), 25-30.
128. Capablo, J.L.; Franco, R.; de Cabezon, A.S.; Alfonso, P.; Pocovi, M.; Giraldo, P. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination. Epilepsia, 2007, 48(7), 1406-1408. (Pubitemid 47063084)
129. Pascual, S.I. Phenotype variations in early onset Pompe disease: Diagnosis and treatment results with Myozyme. Adv. Exp. Med. Biol., 2009, 652, 39-46.
130. Valayannopoulos, V.; Wijburg, F.A. Therapy for the mucopolysaccharidoses. Rheumatology, 2011, 50(S5), v49-59.
131. Engelen, M.A.; Brand, E.; Baumeister, T.B.; Marquardt, T.; Duning, T.; Osada, N.; Schaefer, R.M.; Stypmann, J. Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: A retrospective cohort study of the Fabry Munster Study (FaMuS) data. B.M.J. Open, 2012, 2:e000879.
132. Parenti, G.; Pignata, C.; Vajro, P.; Salerno, M. New strategies for the treatment of lysosomal storage diseases (Review). Int. J. Mol. Med., 2013, 31(1), 11-20.
133. van Gelder, C.M.; Vollebregt, A.A.; Plug, I.; van der Ploeg, A.T.; Reuser, A.J.; Treatment options for lysosomal storage disorders: Developing insights. Expert. Opin. Pharmacother., 2012, 13(16), 2281-2299.
134. Clark, N.E.; Metcalf, M.C.; Best, D.; Fleet, G.W.; Garman, S.C. Pharmacological chaperones for human alpha-N-acetylgalactosa minidase. Proc. Natl. Acad. Sci. U S A, 2012, 109(43), 17400-17405.
135. Garnacho, C.; Dhami, R.; Simone, E.; Dziubla, T.; Leferovich, J.; Schuchman, E.H.; Muzykantov, V.; Muro, S. Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J. Pharmacol. Exp. Ther., 2008, 325(2), 400-408. (Pubitemid 351574785)
136. Lungwitz, U.; Breunig, M.; Liebl, R.; Blunk, T.; Goepferich, A. Methoxy poly(ethylene glycol)-low molecular weight linear polyethylenimine-derived copolymers enable polyplex shielding. Eur. J. Pharm. Biopharm., 2008, 69(1), 134-148. (Pubitemid 351467165)
137. He, Q.; Martinez-Sobrido, L.; Eko, F.O.; Palese, P.; Garcia-Sastre, A.; Lyn, D.; Okenu, D.; Bandea, C.; Ananaba, G.A.; Black, C.M.; Igietseme, J.U. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology, 2007, 122(1), 28-37. (Pubitemid 47222592)
138. Brunetti-Pierri, N.; Ng, P. Progress towards liver and lung-directed gene therapy with helper-dependent adenoviral vectors. Curr. Gene Ther., 2009, 9(5), 329-340.
139. Blits, B.; Derks, S.; Twisk, J.; Ehlert, E.; Prins, J.; Verhaagen, J. Adeno-associated viral vector (AAV)-mediated gene transfer in the red nucleus of the adult rat brain: Comparative analysis of the transduction properties of seven AAV serotypes and lentiviral vectors. J. Neurosci. Methods, 2010, 185(2), 257-263.
140. Bergen, J.M.; Park, I.K.; Horner, P.J.; Pun, S.H. Nonviral approaches for neuronal delivery of nucleic acids. Pharm. Res., 2008, 25(5), 983-998.
141. Hasbrouck, N.C.; High, K.A. AAV-mediated gene transfer for the treatment of hemophilia B: Problems and prospects. Gene Ther., 2008, 15(11), 870-875. (Pubitemid 351712621)
142. Huang, H.; Yu, H.; Tang, G.; Wang, Q.; Li, J. Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gammacyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. Biomaterials, 2010, 31(7), 1830-1838.
143. Keeney, M.; van den Beucken, J.J.; van der Kraan, P.M.; Jansen, J.A.; Pandit, A. The ability of a collagen/calcium phosphate scaffold to act as its own vector for gene delivery and to promote bone formation via transfection with VEGF(165). Biomaterials, 2010, 31 (10), 2893-2902.
144. Lu, W.; Zhang, G.; Zhang, R.; Flores, L.G.2nd; Huang, Q.; Gelovani, J. G.; Li, C. Tumor site-specific silencing of NF-kappaB p65 by targeted hollow
145. Yang, Y.; Zhang, Z.; Chen, L.; Gu, W.; Li, Y. Galactosylated poly(2-(2-aminoethyoxy)ethoxy)phosphazene/DNA complex nanoparticles: In vitro and in vivo evaluation for gene delivery. Biomacromolecules, 2010, 11(4), 927-933.
146. Ren, H.; Boulikas, T.; Lundstrom, K.; Soling, A.; Warnke, P.C.; Rainov, N.G.; Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene-A phase I/II clinical protocol. J. Neurooncol., 2003, 64(1-2), 147-154. (Pubitemid 36992469)
147. Klatzmann, D.; Valery, C.A.; Bensimon, G.; Marro, B.; Boyer, O.; Mokhtari, K.; Diquet, B.; Salzmann, J.L.; Philippon, J. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther., 1998, 9(17), 2595-2604. (Pubitemid 29004632)
148. Rainov, N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther., 2000, 11(17), 2389-2401.
149. Panyam, J.; Labhasetwar, V. Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res., 2003, 20(2), 212-220. (Pubitemid 36277684)
150. Prabha, S.; Zhou, W.Z.; Panyam, J.; Labhasetwar, V. Sizedependency of nanoparticle-mediated gene transfection: Studies with fractionated nanoparticles. Int. J. Pharm., 2002, 244(1-2), 105-115. (Pubitemid 35245451)
151. Dodart, J.C.; Marr, R.A.; Koistinaho, M.; Gregersen, B.M.; Malkani, S.; Verma, I.M.; Paul, S.M. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U S A, 2005, 102(4), 1211-1216. (Pubitemid 40170751)
152. Subramanian, A.; Ranganathan, P.; Diamond, S. L. Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells. Nat. Biotechnol., 1999, 17(9), 873-877. (Pubitemid 29416660)
153. Nakanishi, M.; Akuta, T.; Nagoshi, E.; Eguchi, A.; Mizuguchi, H.; Senda, T. Nuclear targeting of DNA. Eur. J. Pharm. Sci., 2001, 13(1), 17-24. (Pubitemid 32259537)
154. Gorlich, D.; Kutay, U. Transport between the cell nucleus and the cytoplasm. Annu. Rev. Cell. Dev. Biol., 1999, 15 607-660. (Pubitemid 32250388)
155. Bowerman, B.; Brown, P.O.; Bishop, J.M.; Varmus, H.E. A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev., 1989, 3(4), 469-478.
156. Roe, T.; Reynolds, T.C.; Yu, G.; Brown, P.O.; Integration of murine leukemia virus DNA depends on mitosis. EMBO J., 1993, 12(5), 2099-2108. (Pubitemid 23157725)
157. Bukrinsky, M.I.; Haggerty, S.; Dempsey, M.P.; Sharova, N.; Adzhubel, A.; Spitz, L.; Lewis, P.; Goldfarb, D.; Emerman, M.; Stevenson, M. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature, 1993, 365(6447), 666-669. (Pubitemid 23350541)
158. Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J.R.; Bushman, F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 2002, 110(4), 521-529. (Pubitemid 35232295)
159. Wu, X.; Li, Y.; Crise, B.; Burgess, S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science, 2003, 300(5626), 1749-1751. (Pubitemid 36712571)
160. Bushman, F.D. Targeting survival: Integration site selection by retroviruses and LTR-retrotransposons. Cell, 2003, 115(2), 135-138. (Pubitemid 37329577)
161. Narezkina, A.; Taganov, K.D.; Litwin, S.; Stoyanova, R.; Hayashi, J.; Seeger, C.; Skalka, A.M.; Katz, R.A. Genome-wide analyses of avian sarcoma virus integration sites. J. Virol., 2004, 78(21), 11656-11663. (Pubitemid 39390752)
162. Olivares, E.C.; Hollis, R.P.; Chalberg, T.W.; Meuse, L.; Kay, M.A.; Calos, M. P. Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat. Biotechnol, 2002, 20 (11), 1124-1128. (Pubitemid 35285441)
163. Ivics, Z.; Hackett, P.B.; Plasterk, R.H.; Izsvak, Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell, 1997, 91(4), 501-510. (Pubitemid 27508239)
164. Ivics, Z.; Li, M.A.; Mates, L.; Boeke, J.D.; Nagy, A.; Bradley, A.; Izsvak, Z. Transposon-mediated genome manipulation in vertebrates. Nat. Methods, 2009, 6(6), 415-422.
165. Izsvak, Z.; Chuah, M. K.; Vandendriessche, T.; Ivics, Z. Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods, 2009, 49 (3), 287-297.
166. Kren, B.T.; Unger, G.M.; Sjeklocha, L.; Trossen, A.A.; Korman, V.; Diethelm-Okita, B.M.; Reding, M.T.; Steer, C.J. Nanocapsuledelivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J. Clin. Invest., 2009, 119(7), 2086-2099.
167. Stockert, R.J.; Haimes, H.B.; Morell, A.G.; Novikoff, P.M.; Novikoff, A.B.; Quintana, N.; Sternlieb, I. Endocytosis of asialoglycoprotein-enzyme conjugates by hepatocytes. Lab. Invest., 1980, 43(6), 556-563. (Pubitemid 11209843)
168. Zayed, H.; Izsvak, Z.; Walisko, O.; Ivics, Z. Development of hyperactive sleeping beauty transposon vectors by mutational analysis. Mol. Ther., 2004, 9(2), 292-304. (Pubitemid 38256555)
169. Sands, M.S.; Davidson, B.L. Gene therapy for lysosomal storage diseases. Mol. Ther., 2006, 13(5), 839-849.
170. Sands, M.S.; Haskins, M.E. CNS-directed gene therapy for lysosomal storage diseases. Acta Paediatr. Suppl, 2008, 97(457), 22-27. (Pubitemid 351421300)
171. Skorupa, A.F.; Fisher, K.J.; Wilson, J.M.; Parente, M.K.; Wolfe, J.H. Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp. Neurol., 1999, 160(1), 17-27.
172. Bosch, A.; Perret, E.; Desmaris, N.; Heard, J.M. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol. Ther., 2000, 1(1), 63-70.
173. Frisella, W.A.; O'Connor, L.H.; Vogler, C.A.; Roberts, M.; Walkley, S.; Levy, B.; Daly, T. M.; Sands, M.S. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol. Ther., 2001, 3(3), 351-358. (Pubitemid 32514651)
174. Marshall, J.; McEachern, K.A.; Kyros, J.A.; Nietupski, J.B.; Budzinski, T.; Ziegler, R.J.; Yew, N.S.; Sullivan, J.; Scaria, A.; van Rooijen, N.; Barranger, J.A.; Cheng, S.H. Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model. Mol. Ther., 2002, 6(2), 179-189. (Pubitemid 36336125)
175. Ruiz de Garibay, A.P.; Delgado, D.; Del Pozo-Rodriguez, A.; Solinis, M.A.; Gascon, A.R. Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy. Drug. Des. Devel. Ther., 2012, 6, 303-310.
176. Kircheis, R.; Wightman, L.; Wagner, E. Design and gene delivery activity of modified polyethylenimines. Adv. Drug. Deliv. Rev., 2001, 53(3), 341-358. (Pubitemid 34024914)
177. Bivas-Benita, M.; Romeijn, S.; Junginger, H.E.; Borchard, G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur. J. Pharm. Biopharm., 2004, 58(1), 1-6. (Pubitemid 38780998)